Men with castration-resistant prostate cancer who have previously received diethylstilboestrol treatment can still benefit from abiraterone, according to the results of a new study. In a cohort of 247 patients who received abiraterone, 114 (41.6%) men were found to have previously received diethylstilboestrol. The proportion of patients who experienced ≥50% PSA decline were similar for men who had and had not received diethylstilboestrol, in both the prechemotherapy (74.1% versus 85.4%) and postchemotherapy (28.4% versus 35.4%) settings.